Deccan Healthcar (542248)

Score breakdown: P/E: 2/3 · ROCE: 0/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At ₹35.53, Deccan Healthcar trades below its book value of ₹40.97, giving me a P/B of 0.87. A bargain price, yes, but as Graham warned, a low price can be a trap if the business itself is mediocre. The numbers here tell a sober story: ROE is just 2.22% and ROCE only 1.65%. That means every rupee of capital employed earns very little. This is not a franchise with pricing power or a durable moat; it is a small healthcare service provider struggling to grow, with sales down 14.88%. The 614.29% profit growth looks eye-catching, but it is from a tiny base and cannot be taken at face value. In the latest quarter, sales were ₹17 Cr and net profit only ₹1 Cr—thin margins. So the earnings jump is not evidence of a great business. The P/E of 14.74 is not demanding, but a low multiple on weak earnings is not automatically cheap. There is some comfort: the Piotroski F-score of 6 suggests the balance sheet is not deteriorating badly, and no dividend means I get no income while waiting. Also, without promoter holding data or debt-to-equity details, I cannot fully judge management's skin in the game or leverage risk. The stock has moved from ₹6.65 to ₹35.53, so Mr. Market has already re-rated it. I would need to see actual improvement in return on capital and a halt to the sales decline before I call this a true value investment. For now, it remains a possible asset play, but only for those who can verify the book value and wait patiently.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer